CytomX Therapeutics Inc. (CTMX)
CytomX Therapeutics: Cashed Up With Catalysts Ahead
In March, CTMX showcased Varseta-M's potential in late-line metastatic colorectal cancer, although toxicity concerns can't be dismissed. Following the Q1'26 CRC data update, CTMX raised $234.2M, extending its cash runway and enabling broader Varseta-M development. CTMX's cash position of $346.7M supports operations into at least H2'28, with anticipated increased R&D spending as programs expand.
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to earnings of $0.27 per share a year ago.
Small Cap or Megacap: Which Healthcare Stock Is Right for You?
Healthcare companies with different market caps offer different rewards and challenges.
CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level
CytomX Therapeutics (CTMX) has generated significant excitement with strong early data for varsetatug masetecan in refractory colorectal cancer. Phase 1 results show 20–32% response rates and median PFS of 6.8–7.1 months, outperforming current treatments in this setting. CTMX is executing a $250 million equity raise, extending its cash runway and positioning for registrational studies, but remains pre-commercial.
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastatic CRC show rising response rates and strong disease control.
CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.22 per share a year ago.
CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
CytomX Therapeutics, Inc. (NASDAQ: CTMX) will release its fourth-quarter earnings before the opening bell on Monday, March 16.
CytomX Stock Rises 31% in a Month: Here's What You Should Know
CTMX's share jumps 31% in a month after it outlined pipeline progress and 2026 goals led by Varseta-M in advanced colorectal cancer.
CytomX Therapeutics, Inc. (CTMX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CytomX Therapeutics, Inc. (CTMX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CytomX: Easiest Money May Have Been Made, Although Pipeline Remains Compelling
CytomX has confirmed a Q1'26 readout for additional data from its trial of CX-2051 in colorectal cancer. CTMX also now notes it plans to start combination work with CX-2051 and bevacizumab in Q1'26. Financially, CTMX holds ~$158M pro forma cash, guiding for runway through Q2'27, with further fundraising, such as using the Open Market Sales Agreement, possible.
CytomX Therapeutics: Leaning Into The Hype, But What's Next?
CytomX Therapeutics (CTMX) is highlighted as a Buy, driven by optimism for its masked antibody probody platform targeting cancer. Lead candidate CX-2051 shows promising phase 1 results in refractory colorectal cancer, with disease control in nearly all patients and confirmed responses. CTMX holds a strong financial position with $34.2 million in cash and $109.4 million in investments, supporting operations through Q2 2027.
CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.07 per share a year ago.
